Weekly Roundup: Keeping score on the sector
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, its Phase 2-ready, novel, first-in-class and best-in-class therapeutic candidate, to Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company focused on renal disease, for initial development in Acute Kidney Injury (AKI).
Poolbeg Pharma announced they had dosed the first patient in the POLB 001 TOPICAL clinical trial and they had raised £3.5 million of new capital
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced that the first patient has been dosed in the POLB 001 TOPICAL clinical trial. University College London Hospital has now also been activated as a clinical trial site.
The Company also announced that it had raised £3.5 million (before expenses) following a placing of shares on the Aim Market of the London Stock Exchange at an issue price of 6 pence per new Ordinary Share.
Nucleome Therapeutics strengthened its global IP portfolio with a US patent for its core MCC Technology
Nucleome Therapeutics, a pioneering biotechnology company unlocking the therapeutic potential of the regulatory genome through its proprietary 3D genomics platform, announced that the United States Patent & Trademark Office (USPTO) has granted a key US patent for its Micro Capture-C (MCC) technology.
Simris Group AB appointed ADC expert Professor Andreas Pahl as Chief Executive Officer of its subsidiary Simris Biologics GmbH
Simris Group AB announced the appointment of Professor Andreas Pahl as Chief Executive Officer of Simris Biologics GmbH, its wholly owned subsidiary based in Berlin, Germany. Professor Pahl will lead the advancement of the Company’s Microcystin platform and help shape future development programs in line with the strategic direction selected by the Board.
Genopore appointed Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
Genopore, the next-generation proteomics company developing the first semiconductor-based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate effect.
ViCentra appointed Ian Wells as Chief Financial Officer and added medtech veteran Tom West to its Board
ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, announced the appointment of Ian Wells as Chief Financial Officer, effective June 19, 2026, and the addition of Thomas A. West, a veteran U.S. medical technology leader, to its Board of Directors as an Independent Director, effective July 1, 2026. Together, the appointments lay the financial and governance foundation for ViCentra to scale across Europe and enter the U.S. market following a year of sustained operational momentum.
Sofinnova Partners appointed David Evans as Partner
Sofinnova Partners, a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. Evans will invest as part of the Sofinnova Partners Crossover Strategy, playing a key role in its late-stage private and public life sciences investments.
📺Optimum TV
How does SV Health Investors decide which early-stage biotechs to invest in, and which to pass on?
In this week’s episode of Optimum TV, Charles Dunn, Principal in SV’s Biotech team, also shares insights on mid-2026 market trends, investment strategies, and the future of drug development – emphasising the importance of scientific innovation and regulatory adaptation.
Watch the episode here and subscribe to our YouTube channel.
👥Industry events
Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026
Maximising Europe’s Potential – The theme of Optimum’s Annual Healthcare Investor Conference 2026.
The invitation only event takes place on Thursday 8th October and features leading speakers from the healthcare and investment communities. Register your interest in attending today: https://www.optimumcomms.com/irconference2026/
Follow us on LinkedIn to hear updates on speakers and panellists, as they are announced.
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director Zoe Bolt will be attending BIO-Europe 2026, one of the leading international partnering events for the life sciences industry.
The team look forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
Plan ahead for Europe’s busiest week in healthcare 🌍
Jefferies Global Healthcare Conference & Life Sciences Week – London | 15–20th Nov 2026
Join the mailing list to receive the official networking event guide, produced by Catalyst Advisors and Optimum Strategic Communications in partnership with Jefferies.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
